Chapter 20: Pharmacologic Management in Gerontologic Nursing

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Let's start with a number that actually made me stop and reread the page in our source material today.

Ninety -four percent.

According to the data we have here from Chapter 20 of Ontologic Nursing,

ninety -four percent of community dwelling adults aged sixty -five to seventy -four are taking medications.

It's a staggering figure, isn't it?

It really is.

And just to be clear, that's not just one vitamin a day.

We're talking about a complex mix of prescriptions, over -the -counter meds, and dietary supplements.

Exactly.

And when you break that down further, it becomes even more revealing about, well, the state of modern aging.

How so?

You have 81 percent of that demographic taking prescription drugs regularly and nearly half forty -six percent taking over -the -counter medications.

It really paints a picture of the elderly body not just as a biological entity, but as a chemically managed ecosystem.

It does.

And that sets up the core conflict we really need to unpack in this deep dive.

On one hand, these drugs are absolute miracles.

They manage chronic conditions like hypertension and diabetes, they extend life, they maintain well -being.

But on the other hand, in an aging body, these same life -saving chemicals can turn into dangerous, even life -threatening risks.

Precisely.

And that's why Chapter 20 of Gerontologic Nursing is such a critical text for us to decode today.

Yeah.

We aren't just talking about memorizing a list of drug names or dosages here.

No.

This is a mission to understand the fundamental science of pharmacologic management in the elderly.

For the nursing students listening, or anyone caring for an older adult, this is about translating dense biological processes.

Pharmacokinetics and pharmacodynamics.

Right.

Translating that into practical, life -saving knowledge.

Right.

Because the margin for error gets razor thin the older we get.

Right.

So here's our roadmap for this deep dive.

We're going to trace the journey a drug takes through the aging body step -by -step.

We're going to look at the do -not -fly list of medications known as the beers criteria.

We'll get into specific drug classes that cause the most trouble like psychotropics, cardiovascular meds.

And finally,

we're going to shine a light on a hidden epidemic,

substance abuse in the elderly.

It's a lot of ground to cover.

It is.

But if we connect this to the bigger picture, this knowledge is the difference between helping a patient and accidentally harming them.

It transforms the nurse from just a pill dispenser into a safety barrier.

Okay, so let's jump right in.

Section one, the drug's journey.

The technical term used in the chapter is pharmacokinetics.

Which is, simply put, what the body does to the drug.

Right.

When you swallow a pill, it goes on a four -stage journey.

Absorption, distribution, metabolism, and excretion.

And the key takeaway from this chapter is that aging changes every single step of that map.

Okay, let's start with phase one then.

Absorption.

Most of us take pills orally.

What happens to that process when we hit 70 or 80?

The text mentions quite a few gastric changes.

Well, biologically, the digestive engine just slows down.

You have decreased gastric acid secretion, which means the stomach environment is less acidic.

You have slowed gastric emptying, meaning food and drugs sit in the stomach longer.

And you have reduced blood flow to the GI tract overall.

So the logical assumption, and I'm sure one many students make, is that this means the conveyor belt slows down, fewer packages get delivered.

But fascinatingly, the data shows that while the rate of absorption might be slower, the total amount absorbed,

the bioavailability usually doesn't change all that much.

The drug still gets in.

So it just takes the scenic route.

That's a perfect way to put it.

It eventually arrives, but the timing is off.

And the clinical implication here is huge.

Think about pain medication.

Okay.

The first dose of a new drug might take significantly longer to kick in than you'd expect in a younger person.

It's a delay, not a blockade.

And if a nurse doesn't understand that lag time, they might think the drug isn't working and administer a second dose too soon, leading to an overdose once everything finally hits the bloodstream.

That is a critical distinction.

The text also flagged a specific issue with topical drugs, right?

Creams and patches.

Yes.

We tend to think of skin as just skin, but for transdermal patches like fentanyl patches or nicotine patches, they often rely on a layer of subcutaneous fat to help regulate absorption.

And older adults naturally lose that subcutaneous fat.

They do.

So the drug delivery becomes erratic.

With less fat, absorption might be reduced.

Or because older skin is thinner and more vascular in some areas, you might get a rapid dump of the drug into the system.

It removes the predictability we rely on with patches.

Okay.

So the drug is in the system.

Now we hit phase two, distribution.

This is where the body's composition really matters.

The chapter talks a lot about the water to fat ratio.

This is a concept that creates a lot of aha moments for students.

As we age, our total body water decreases significantly and our percentage of body fat generally increases.

And that creates a fork in the road, depending on the drug.

Precisely.

It depends on whether a drug dissolves in water or fat.

Let's break that down.

Start with water -soluble drugs.

The text lists things like degoxin, lithium, and ethanol.

Right.

So think of the human body as a container of water.

An older body is a smaller container of water.

Okay.

So if you put the standard dose of a water soluble drug like degoxin into that smaller container, the concentration of the drug spikes.

It's like dissolving a packet of Kool -Aid in a shot glass instead of a picture.

That's a perfect analogy.

The amount of powder is the same, but the intensity, the concentration is way higher.

And this significantly increases the risk of toxicity, even if the dose is technically normal for an adult.

And what about the flip side?

The fat -soluble drugs.

These are drugs like benzodiazepines, your valiums and Xanaxes, or certain anesthetics.

They are lipophilic.

They love fat.

And the older body has more fat tissue.

So these drugs get sucked up and stored in that fat.

The fat tissue acts like a storage tank, a reservoir.

So the body just hangs onto them.

For much longer, yes.

It leaks them back into the bloodstream slowly over time.

This extends the half -life of the drug, so a sedative that should wear off in a few hours might linger for days, causing drowsiness and confusion long after the patient took the pill.

And there's another major player in distribution that the text highlighted.

Protein binding.

This involves albumin.

Yes, specifically serum albumin.

Think of albumin as a fleet of buses traveling through the bloodstream.

Okay.

Many drugs, like warfarin or phenytoin, are designed to hop on this bus.

When the drug is attached to the protein, it's inactive.

It's just a passenger.

It only becomes active and able to do its job when it steps off the bus.

But if you're a malnourished or frail older adult?

Your albumin levels drop.

You have fewer buses on the road.

So you have more passengers stranded at the station.

Or in this case, more free drug floating around.

Exactly.

More free drug floating around in the bloodstream.

Because there's no protein to bind it, a larger percentage of the drug remains in its active potent form.

So a standard dose of warfarin in someone with low albumin has the effect of an overdose because there's so much free drug hitting the receptors.

This is where it gets really interesting for me, seeing how these physiological tweaks completely change the math.

A normal dose becomes toxic without anyone changing a thing.

Let's move to phase three, metabolism.

The liver.

The liver is the body's primary detox center.

But as we age, liver size decreases.

And more importantly, hepatic blood flow drops significantly, sometimes by as much as 40%.

And this impacts something called the first pass effect.

Okay, let's unpack that.

What exactly is the first pass effect?

Usually when you swallow a pill and it's absorbed from the gut, it doesn't go straight to the heart or brain.

It goes directly to the liver first.

The liver acts as a gatekeeper, breaking down or metabolizing a large chunk of that drug before it ever reaches the rest of the body.

That's the first pass.

So it filters out a lot of the potency.

Correct.

But because blood flow is reduced in older adults, the gatekeeper is essentially asleep on the job.

The liver doesn't catch as much of the drug.

So less drug gets deactivated.

Exactly.

More active drugs survives the liver and enters systemic circulation.

Again, just like with the water volume issue, this raises the risk of toxicity.

And the text also mentions the cytochrome P450 enzyme system.

Yes, that's the engine of metabolism.

While some phases of this system stay stable, others, specifically phase I oxidation reactions, tend to slow down.

It's inconsistent, which is why individual monitoring is so key.

Which brings us to the final stop on the journey.

Phase IV, excretion, the kidneys.

This is arguably the most important takeaway for nurses in this entire chapter.

Kidney function decreases with age, period.

The nephrons, the filtering units die off, and blood flow drops.

The kidneys just don't clear toxins as efficiently as they used to.

Which means drugs stay in the body longer and can build up.

Your accumulation, exactly.

And the text had a huge warning here about how we measure kidney function.

It practically screamed that serine creatinine is not a reliable indicator in older adults.

It is so deceptive, we're all trained to think high creatinine equals bad kidneys.

But remember, creatinine is a waste product of muscle breakdown.

Who has low muscle mass?

Older, frail adults.

Exactly.

So they aren't producing much creatinine to begin with.

You could have a patient with kidneys that are functioning at 30 % capacity, but their blood test shows a normal creatinine level.

That sounds incredibly dangerous.

Yeah.

If a nurse looks at that normal number and assumes the kidneys are fine.

They might administer a nephrotoxic drug or a standard dose that the kidneys can't handle, sending the patient into renal failure.

So what's the solution?

If we can't trust creatinine, what do we look at?

You must look at the glomerular filtration rate, or GFR.

The text specifically mentions formulas like the MDRD6 or the Koch -Kroft -Gault equation.

And those give a better picture.

They give you the real picture of how well the kidneys are clearing toxins, because they take age, weight, and gender into account.

If you dose based on creatinine alone, you are flying blind.

So looking at this whole journey, absorption is delayed, distribution concentrates the drug, metabolism fails to break it down, and excretion fails to clear it out.

It seems like the entire system is rigged to keep drugs in the body longer and at higher concentrations.

That is the perfect summary.

And it leads to the universal mantra of gerontologic pharmacology found in this chapter,

start low and go slow.

Start low and go slow.

You assume the system is compromised until proven otherwise.

I love that.

Okay, let's pivot to section two, pharmacodynamics.

If kinetics is the journey,

how the drug moves,

dynamics is the destination.

What the drug does to the body.

Correct.

And the destination changes too.

We see alterations in receptor sensitivity.

Me neither.

An older adult might be super sensitive to a drug, or conversely, the drug might not work as well.

For example, the beta -adrenergic receptors change.

Older adults often have a reduced response to beta blockers and beta agonists.

The receptors just don't hear the signal as clearly.

But on the flip side, they are hypersensitive to other things.

Oh yes,

specifically to anticholinergic effects.

Drugs that block acetylcholine can cause severe confusion, dry mouth, and urinary retention in older adults much, much faster than in younger people.

And on top of that, the body's ability to bounce back with what the book calls homeostasis is compromised.

Yes, the body's reflexes are slower.

Think about the bare receptors that control blood pressure.

If a drug drops your blood pressure, a young body quickly clamps down the vessels and speeds up the heart to compensate.

But an older body reacts much slower.

So they stand up, the blood pressure drops, the body doesn't react.

And they fall.

And they fall.

Orthostatic hypotension is a major pharmacodynamic risk.

This variability brings us to a crucial tool mentioned in the text.

The Beer's Criteria.

The Beer's Criteria?

I've heard this described as the do -not -fly list for meds.

That's a great way to put it.

It's a list updated regularly by the American Geriatric Society, identifying potentially inappropriate medications or PIMs.

So these are drugs where the risks just outweigh the benefits for most older adults.

So the vast majority, yes.

And the stats on this are worrying.

The source says 20 % of community older adults and nearly half 48 % of hospitalized older adults are prescribed these inappropriate meds.

Yeah, it's a huge problem.

What are the common culprits we should be looking for?

You see things like propoxyphene, which offers poor pain relief but high toxicity.

You see diffenhydramine standard benadryl, which we just mentioned is a potent anticholinergic.

And you see older antidepressants like amitriptyline, which carries heavy risks of confusion, falls, and cardiac issues.

But here is the counterpoint that I found fascinating in the chapter.

The text mentions that while the Beer's list is vital, it's not the whole story.

No, it's not.

Focusing only on the bad list can give a false sense of security.

That is a crucial nuance.

A study of emergency department visits showed that one -third of adverse drug events were caused by three very common appropriate drugs.

And there were?

Insulin, warfarin, and digoxin.

Wow.

So just because it's not on the Beer's list doesn't mean it's safe.

Exactly.

Those three are chemically necessary for many people, but they have narrow therapeutic windows.

A tiny error in insulin dosing causes hypoglycemia.

A shift in warfarin management leads to bleeding.

It's always about balancing risk versus benefit.

And that balance extends to quality of life.

Absolutely.

The text gave the example of Atenolol.

Great for blood pressure, but if it causes erectile dysfunction, the patient might stop taking it.

Or Metoclopramide for gastric reflux.

Great for the stomach, but it can cause movement disorders.

So this raises an important question for the nurse.

It does.

If a patient is refusing a med,

don't just mark refused in the chart and walk away.

Please don't.

Find out why.

It might be ruining their quality of life.

Maybe there's an alternative, like an ACE inhibitor instead of a beta blocker, that solves the problem without the side effect.

We have to treat the person, not just the number on the monitor.

That leads perfectly into section three, the danger zones.

Specifically, interactions and polypharmacy.

You used that term polypharmacy earlier.

How is that officially defined here?

It's defined broadly as giving medications without a clear indication, giving duplicate meds or just giving too many meds concurrently.

It happens because older adults have multiple chronic conditions.

Multimorbidity, yeah.

They see a cardiologist, a nephrologist, a primary care doctor, and none of them are looking at the same chart.

It's like a kitchen with too many cooks, and everyone is adding salt to the soup without talking to each other.

The result is a toxic soup.

This environment is a breeding ground for interactions.

We have drug interactions.

One mechanism is displacement, which connects back to our albumin bus analogy.

If two drugs want the same seat on the bus, one gets kicked off and becomes toxic.

Or antagonism.

Right.

If you take a beta blocker for hypertension and a beta agonist for asthma, they are literally fighting for the same receptor sites.

One turns the switch on, the other turns it off.

So they just cancel each other out.

Or worse, then you have the classic warfarin and aspirin combo.

Both thin the blood, put them together, and you have a massive bleeding risk.

Then you have drug food interactions.

This is something patients probably overlook because they don't think of food as chemistry.

Oh, absolutely.

But the grapefruit juice effect is legendary in pharmacology for a reason.

Oh yes, the grapefruit rule.

Why is that fruit specifically such a villain?

It contains these compounds, ferronocoumarins, which inhibit the CYP3A4 enzymes in the gut wall.

Those enzymes are supposed to break down many drugs.

So if you inhibit the enzyme...

The drug like a calcium channel blocker or a statin doesn't get broken down.

It floods the system, leading to toxic levels.

One pill with grapefruit juice can equal the potency of 10 tils with water.

That is terrifying.

It is.

And it's not just grapefruit.

The text mentioned fiber and digoxin.

Yes, fiber can bind to the digoxin in the gut, absorbing it so the body never gets the dose.

If an older adult eats a huge bowl of bland cereal for constipation at the same time they take their heart med, they might be neutralizing the drug completely.

And vitamin K.

Vitamin K is the antidote to warfarin.

It helps blood clot.

So if a patient on warfarin suddenly decides to start eating huge spinach salads every day, they're loading up on vitamin K and effectively turning off their blood thinner.

It seems like everything is a potential minefield.

Even drug disease interactions.

Absolutely.

This is where the nurse has to know the patient's history.

Giving N -acides like ibuprofen to someone with kidney disease can push them into renal failure.

Because N -acides reduce kidney blood flow.

Exactly.

Giving beta blockers to someone with COPD can trigger breathing issues.

Giving anticholinergics to a man with an enlarged prostate can cause acute urinary retention.

And amidst all these biological interactions, we have the human element.

Medication errors.

The text highlights the six rights of administration.

Right.

Drug, dose, time, route, patient, documentation.

But it points out that so many errors happen at home.

That's the reality.

Patients are discharged quicker now.

They're managing complex regimens at home with poor vision, cognitive decline, or just confusion.

This is where the nurse's role as educator is paramount.

You can't just hand them a paper.

You have to ensure they can actually manage the regimen.

Let's dive deeper into some specific drug classes in section four.

We've touched on some, but let's get specific.

Psychotropics.

The text calls this the chemical restraint warning.

This is a heavy topic, specifically regarding antipsychotics.

These drugs are often prescribed for the behavioral symptoms of dementia, agitation, aggression, wandering.

It's seen as a way to control the patient.

It is.

But the FDA has issued a black box warning.

What does the warning say?

It explicitly states that using antipsychotics in elderly dementia patients increases the risk of mortality.

Wow.

It increases the risk of stroke, heart failure, and pneumonia.

We are essentially trading behavioral control for a higher chance of death.

That's a stark trade -off.

And yet they are still prescribed.

They are.

And beyond mortality, they cause side effects like extra -pure middle symptoms, EPS tremors, rigidity, that shuffling walk,

or tardive dyskinesia, which involves repetitive involuntary movements of the face and tongue.

And that can be permanent.

It can be permanent even if you stop the drug.

What about anxiety and insomnia?

I feel like everyone knows someone on a benzodiazepine.

And they are incredibly risky for this demographic.

Long -acting benzos like diazepam valium are fat -soluble, as we discussed.

They stay in the system forever.

Leading to falls, fractures, memory loss.

Significant memory loss, yes.

The text strongly advises avoiding them.

If you must treat anxiety, buspirone is a safer alternative, though it takes weeks to work, so it's not a quick fix.

And for sleep,

the text warns about the benadryltrap.

Yes.

Look at the label of almost any OTC sleep aid.

Tylenol PM, Zizquel.

The active ingredient is diphenhydramine.

Benadryl.

People think it's over -the -counter, it's safe.

But for an older adult, it's an anticholinergic bomb.

It causes dry mouth, urinary retention, constipation, and confusion.

It's a delirium trigger in a bottle.

Moving to cardiovascular meds.

The JNC7 guidelines are mentioned in the chapter.

Right.

For hypertension, thiazide diuretics are often the first line of defense.

They work well and are generally safe.

But we have to be careful with digoxin, which we keep mentioning.

The narrow therapeutic window.

A very narrow therapeutic window.

The difference between a helpful dose and a toxic dose is tiny.

And what does digoxin toxicity look like?

It's tricky.

It presents as nausea, loss of appetite, and visual disturbances, classically.

Seeing yellow halos around lights.

If a patient complains of that, you need to check their levels immediately.

One thing I found surprising was the section on supplements.

There's this myth that natural equals safe.

A dangerous myth.

The liver doesn't care if a chemical came from a root or a lab.

It has to metabolize it.

So gingo biloba, for instance.

Often taken from memory,

but it increases bleeding risk.

If you take gingo with aspirin, you are asking for trouble.

And St.

John's word.

That one is notorious for interactions.

It interacts with antidepressants, specifically MAOIs, potentially causing a hypertensive crisis.

But it also induces liver enzymes, meaning it makes the liver chew up other drugs faster.

It can make other drugs less effective.

It can render life -saving medications like Dagoxin or Warfarin ineffective, because the body clears them too quickly.

So the nursing priority here is clear.

You have to ask.

You can't just ask what medications do you take.

No.

You have to ask what vitamins, herbs, or teas do you drink.

Because the patient doesn't count them as drugs, but their liver certainly does.

Let's move to section five.

Adherence.

The text makes a point to reframe non -compliant to non -adherence.

Why the shift in language?

It's an important shift.

Non -compliance sounds like the patient is being difficult on purpose, like a rebellious child.

Right.

It's judgmental.

Non -adherence recognizes that there are usually valid barriers preventing them from following the plan.

It moves the nurse from a place of judgment to a place of investigation.

And what are the main barriers identified in the text?

Financial factors are huge.

Many older adults are on fixed incomes.

They fall into the donut hole of Medicare coverage where they have to pay out of pocket.

So they start splitting pills.

They split pills in half to make them last longer, which means they're getting a subtherapeutic dose.

They aren't trying to be difficult.

They are trying to survive.

Then there are the physical barriers.

Think about arthritis.

Can you open a childproof cap if your hands are stiff and painful?

Can you read the microscopic print on the label if you have cataracts or macular degeneration?

And the cognitive aspect.

Simple forgetfulness.

Or confusion.

If the regimen is complex, take this one at 8 a .m.

This one with food.

This one on an empty stomach.

Mistakes are inevitable.

There's also an education gap mentioned.

Patients stopping antibiotics because they feel better.

Or stopping blood pressure meds because they don't feel them working.

Hypertension is the silent killer.

You don't feel high blood pressure.

So patients think the drug is doing nothing and stop taking it.

So what can nurses do?

Simplify.

Try to get the regimen down to once daily dosing if possible.

Use pill organizers.

Encouraging the use of one pharmacy is huge so the pharmacist can catch interactions.

And the brown bag method.

I love the brown bag method.

Tell us about that.

It's the gold standard for assessment.

You ask the patient or family to put everything they take,

prescriptions, OTCs, vitamins, old bottles from the back of the cabinet, new bottles, into a brown bag and bring it to the clinic.

And you just dump it out.

You dump it out on the table.

And you will be amazed at what you find.

You'll find antibiotics from 1998.

You'll find three different bottles of the same generic drug with different names because they switched pharmacies.

And the patient is taking all three.

It's the only way to see the actual reality of what they are consuming.

That brings us to our final and perhaps most sobering section.

The hidden epidemic.

Substance abuse in older adults.

We often think of substance abuse as a young person's problem.

But the baby boomers are aging.

This is a generation that grew up with a different cultural relationship to drugs than the previous generation.

They have higher rates of illicit drug tolerance.

And they are bringing those habits into their senior years.

Let's talk about alcohol first.

The text distinguishes between early onset and late onset alcohol abuse.

Early onset refers to the folks who have been heavy drinkers their whole lives.

They usually have severe health issues, cirrhosis, cognitive decline by the time they retold age.

But late onset is different.

Very different.

These are people who start drinking heavily later in life.

And what triggers that?

Usually loss.

The death of a spouse, forced retirement, losing their home, the loss of independence.

Alcohol becomes a coping mechanism for grief and loneliness.

And it's hard to detect, isn't it?

Extremely.

If an 80 -year -old falls, has bruises, or seems a bit confused, we assume it's just aging.

We assume it's dementia or a balance issue.

We don't assume they're drunk.

We don't.

But biologically, the older liver cannot process alcohol.

The tolerance level plummets.

A drink that gave them a mild buzz at 40 might make them stumble and fall at 70.

What tools do we have for this?

We have to scream.

The text mentions the CAGE questionnaire and the MASTG, which is the geriatric version of the Michigan alcoholism screening test.

Nurses have to be willing to ask the uncomfortable questions.

And it's not just alcohol.

Prescription drug abuse is rising.

Opioids and benzodiazepines are the main culprits.

Signs to watch for are patients losing prescriptions frequently, using multiple doctors to get scripts, or complaining of pain that seems disproportionate to their condition.

Finally, the text touches on nicotine.

It says, it's never too late to quit.

But there's a pharmacokinetic twist here I hadn't realized.

It's fascinating.

Smoking actually interacts with drugs by inducing liver enzymes.

It revs up the metabolism.

So a smoker might need a higher dose of a drug, like theofaniline or certain sedatives, to get the same effect.

Because their liver is chewing it up so fast.

Exactly.

So what happens if they quit smoking?

That induction stops.

The metabolism slows down.

Suddenly, that normal high dose they were taking becomes a toxic overdose because the interaction is gone.

Wow.

So if a patient quit smoking, the nurse needs to flag that for the provider because medication dosages might need to be lowered immediately.

I hadn't connected those dots.

It really shows how interconnected all of this is.

So we've covered the journey, the dangers, the drugs, and the abuse.

In a comprehensive landscape.

So what does this all mean?

If you're a nursing student listening to this, what's the synthesis?

The big, so what?

The synthesis is this.

You, the nurse, are the final barrier.

The older body is physically vulnerable.

The kidneys are fading.

The liver is slow.

The water -fat balance is skewed.

The pharmacokinetics are working against them.

The pharmacodynamics are unpredictable.

And the social factors, like cost and isolation, complicate adherence.

It sounds like the key takeaway is vigilance.

Vigilance and knowledge.

Understanding that normal aging changes the rules of the game.

You can't just follow the standard dosage chart.

You have to look at the GFR, check the albumin, ask about the herbal tea, and dump out the brown bag.

That knowledge is the foundation of patient safety.

And here's a thought to leave you with, something to mull over.

We talked about the baby boomers.

As this generation, which is larger and has a different relationship with substances than the previous one, continues to age,

we are potentially facing a tidal wave of substance abuse issues that our health care system, and specifically geriatric care, isn't really designed for.

That is the looming challenge.

We are built to treat hypertension and diabetes.

We aren't necessarily built to treat an 85 -year -old managing heroin recovery alongside Alzheimer's.

How the role of the nurse evolves to meet this new challenge will define the next era of care.

It's a sobering thought.

It is.

Indeed.

Well, thank you for unpacking this dense chapter with us.

It's been a true deep dive.

My pleasure.

It's vital information.

This has been the Last Minute Lecture Team signing off.

Stay curious and stay safe out there.